Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 7/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469847 | 0.78 | IDO1 (0.51) | IDO1GABRA5TDO2LCKBRD9 | |
| SCHEMBL3356849 | 0.75 | GABRA5 (0.50) | IDO1GABRA5TDO2LCKGABRA1 | |
| SCHEMBL13281957 | 0.72 | IDO1 (1.00) | IDO1TDO2LCK | |
| SCHEMBL13281956 | 0.72 | IDO1 (1.00) | IDO1TDO2LCK | |
| SCHEMBL19749323 | 0.72 | IDO1 (1.00) | IDO1TDO2LCK | |
| SCHEMBL13281959 | 0.72 | IDO1 (1.00) | IDO1TDO2LCK | |
| SCHEMBL20621027 | 0.71 | IDO1 (0.40) | IDO1GABRA5LCKBRD9GABRA1 | |
| SCHEMBL22189146 | 0.71 | IDO1 (0.40) | IDO1GABRA5LCKBRD9GABRA1 | |
| SCHEMBL20620953 | 0.71 | IDO1 (0.40) | IDO1GABRA5LCKBRD9GABRA1 | |
| SCHEMBL22200847 | 0.70 | IDO1 (0.42) | IDO1GABRA5TDO2LCKBRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842442-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | PREC PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20190225618-A1 | IDO Inhibitors | MAUTINO MARIO (US) | 2019-07-25 | — | — | US | disclosed |
| US-9850248-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225618-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885GABRA5 2847/4885TDO2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.